Clinical Decision Summary Patients and clinicians weighing Mounjaro versus retatrutide face a choice between an approved, commercially accessible drug with 72-week phase 3 data and an investigational agent with 48-week phase 2 data that shows numerically superior weight loss but substantially higher GI discontinuation rates
Synergy with GHRH Analogs Same as GHRP-6: stacking GHRP-2 with CJC-1295 (or sermorelin or tesamorelin) produces a multiplicatively stronger GH pulse than either compound alone
Use it as an adjunct to diet and training
Immunohistochemistry Immunohistochemistry for calcitonin, synaptophysin, insulin, glucagon, somatostatin, and pancreatic polypeptide (PP) was performed on formalin-fixed tissues
Common adverse reactions reported in over 5% of patients treated with semaglutide include: Nausea Vomiting Diarrhea Abdominal pain Constipation Call your healthcare provider immediately if you experience any signs of an allergic reaction, including wheezing, chest tightness, fever, itching, bad cough, blue skin color, severe behavioral problems, chest pain or pressure, fast heartbeat, severe dizziness, passing out, nervousness and excitability, severe headache, or fits or swelling of the face, lips, tongue, or throat, How to reduce semaglutide side effects Your provider may start your weekly injections at a low dose and gradually increase to the prescribed dosage to minimize potential side effects
.webp)
